Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 213

Results For "GE"

8420 News Found

Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug
R&D | November 23, 2025

Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug

Landmark studies have shown that rapid TXA administration can significantly reduce mortality


AstraZeneca to invest $2 billion in Maryland manufacturing expansion
News | November 22, 2025

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan


India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions
Healthcare | November 21, 2025

India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions

According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic


Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
News | November 21, 2025

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub


Thyrocare launches comprehensive GLP-1 health check across India
Healthcare | November 21, 2025

Thyrocare launches comprehensive GLP-1 health check across India

Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion


Lilly expands biotech footprint with new Gateway Labs in Philadelphia
R&D | November 21, 2025

Lilly expands biotech footprint with new Gateway Labs in Philadelphia

The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies


FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
Drug Approval | November 21, 2025

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options


AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
Drug Approval | November 21, 2025

AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients

The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study


Merck’s two-drug HIV regimen hits phase 3 success
Clinical Trials | November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks